Immutep

Historical price data

Immutep is a global leader in the development of immunotherapies targeting the LAG-3 immune checkpoint, with a mission to deliver safe and effective treatments for cancer and autoimmune diseases. The company's strategy is built on a multi-modal LAG-3 platform, featuring its lead clinical asset eftilagimod alfa (efti), a first-in-class MHC Class II agonist, and several other clinical-stage candidates. With strategic partnerships with major pharmaceutical companies and a pipeline advancing in key oncology indications, Immutep is positioned to capitalize on the growing immuno-oncology market.

A multi-modal immunotherapy platform centered on the Lymphocyte Activation Gene-3 (LAG-3) pathway, featuring a first-in-class soluble LAG-3 MHC Class II agonist (efti), antagonist (blocking) antibodies, and agonist antibodies for autoimmunity.